ALDX EQUITY ACTION REMINDER: Faruqi & Faruqi, LLP Reminds Aldeyra Therapeutics (ALDX) Investors of Securities Class Action Deadline on May 29, 2026
Faruqi & Faruqi, LLP is reminding investors of Aldeyra Therapeutics (ALDX) about the May 29, 2026, deadline to seek lead plaintiff status in a federal securities class action. The lawsuit alleges that Aldeyra made false and misleading statements regarding its drug candidate reproxalap, whose clinical trial results were inconsistent and ultimately led to the FDA rejecting its NDA due to insufficient efficacy evidence. This rejection caused Aldeyra's stock price to fall significantly, harming investors who purchased securities between November 3, 2023, and March 16, 2026.
ALDX Investor Alert: Aldeyra Therapeutics Securities Fraud Lawsuit - Investors With Losses May Seek to Lead the Class Action After Company Allegedly Submitted Incomplete Disclosures: SueWallSt
SueWallSt has issued an investor alert regarding a securities fraud lawsuit against Aldeyra Therapeutics (NASDAQ: ALDX). The lawsuit alleges the company made misleading statements about the consistency and reliability of its drug candidate reproxalap's clinical trial results. Investors who purchased ALDX shares between November 2023 and March 2026 and suffered losses are encouraged to contact SueWallSt to potentially lead the class action before the May 29, 2026, deadline, following a 70.7% stock decline after the FDA issued a Complete Response Letter citing "inconsistency of study results."
Is Aldeyra Therapeutics on the Brink of a Breakthrough with Reproxalap
Aldeyra Therapeutics is approaching a critical FDA PDUFA date of March 16, 2026, for its dry eye drug, reproxalap, following two prior Complete Response Letters. The company has addressed previous FDA concerns with new clinical data, leading to a resubmission and an extended review period, which could suggest a more thorough regulatory path. If approved, reproxalap has the potential to activate a significant partnership with AbbVie, offering Aldeyra a substantial financial injection and leveraging AbbVie's market infrastructure.
Robbins LLP Reminds ALDX Investors of the Pending Class Action Lawsuit; Harmed Investors Should Contact the Firm for Information About Leading the Class Action Against Aldeyra Therapeutics, Inc.
Robbins LLP is reminding investors of a pending class action lawsuit against Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) for alleged misleading statements regarding its lead drug candidate, reproxalap. The lawsuit covers investors who purchased ALDX securities between November 3, 2023, and March 16, 2026, and seeks to recover losses after the FDA issued a Complete Response Letter citing inconsistent and unreliable clinical trial results, causing a significant stock price drop. Shareholders have until May 29, 2026, to submit papers to the court to serve as lead plaintiff.
Robbins LLP Reminds ALDX Investors of the Pending Class Action Lawsuit; Harmed Investors Should Contact the Firm for Information About Leading the Class Action Against Aldeyra Therapeutics, Inc.
Robbins LLP is reminding investors of a class action lawsuit filed against Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) for allegedly misleading investors about its lead drug candidate, reproxalap, between November 3, 2023, and March 16, 2026. The lawsuit claims that Aldeyra failed to disclose inconsistencies in clinical trial results for reproxalap, leading to a significant stock drop after the FDA issued a Complete Response Letter in March 2026 citing lack of efficacy evidence. Shareholders who purchased ALDX securities during this period may be eligible to participate, with a lead plaintiff deadline of May 29, 2026.
Bronstein, Gewirtz & Grossman LLC Urges Aldeyra Therapeutics, Inc. Investors to Act: Class Action Filed Alleging Investor Harm
Bronstein, Gewirtz & Grossman LLC has filed a class action lawsuit against Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) on behalf of investors who purchased securities between November 3, 2023, and March 16, 2026. The lawsuit alleges that Aldeyra made false and misleading statements about the clinical trials of its drug candidate, reproxalap, claiming inconsistent results made purported positive findings unreliable. Investors are urged to join the case by May 29, 2026, to request lead plaintiff status.
Bronstein, Gewirtz & Grossman LLC Urges Aldeyra
Bronstein, Gewirtz & Grossman LLC has filed a class action lawsuit against Aldeyra Therapeutics, Inc. (NASDAQ: ALDX), alleging that the company made false and misleading statements regarding the inconsistent results of its drug candidate reproxalap's clinical trials. The lawsuit covers investors who purchased Aldeyra securities between November 3, 2023, and March 16, 2026, and urges them to join the case. The firm is seeking to recover damages for investors and represents them on a contingency fee basis.
ALDX Investor Alert: Aldeyra Therapeutics Securities Fraud Lawsuit - Investors With Losses May Seek to Lead the Class Action After Company Allegedly Omitted Inconsistent Trial Data: Levi & Korsinsky
Levi & Korsinsky, LLP has filed a securities class action lawsuit against Aldeyra Therapeutics (NASDAQ: ALDX) on behalf of investors who purchased shares between November 3, 2023, and March 16, 2026. The lawsuit alleges that Aldeyra's leadership made misleading statements about the consistency and reliability of reproxalap clinical trial results, which were later revealed by the FDA to be inconsistent and unreliable, causing a 70.7% stock drop. Investors who suffered losses may seek to lead the class action by the May 29, 2026 deadline.
ALDX Investors Have Opportunity to Lead Aldeyra Therapeutics, Inc. Class Action Lawsuit – Contact Bronstein, Gewirtz and Grossman, LLC Today!
Bronstein, Gewirtz & Grossman, LLC has announced a class action lawsuit filed against Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) for alleged violations of federal securities laws. The lawsuit claims that Aldeyra made false and misleading statements regarding the inconsistent and unreliable results of its reproxalap clinical trials. Investors who purchased Adeyra securities between November 3, 2023, and March 16, 2026, are encouraged to join the lawsuit and may request to be appointed as lead plaintiff by May 29, 2026.
Portnoy Law Firm Announces Class Action on Behalf of Aldeyra Therapeutics, Inc. Investors
The Portnoy Law Firm has announced a class action lawsuit against Aldeyra Therapeutics, Inc. on behalf of investors who purchased securities between November 3, 2023, and March 16, 2026. The lawsuit alleges that Aldeyra failed to disclose the inconsistency and unreliability of its reproxalap clinical trial results, leading to a significant stock price drop following a Complete Response Letter from the SEC. Investors are urged to contact the firm by May 29, 2026, to discuss their legal rights.
ALDX DEADLINE: The Gross Law Firm Reminds Aldeyra Therapeutics, Inc. Investors of Upcoming Securities Class Action Deadline
The Gross Law Firm is notifying investors of Aldeyra Therapeutics, Inc. (ALDX) about an upcoming securities class action deadline of May 29, 2026. The lawsuit alleges that Aldeyra Therapeutics made materially false and misleading statements regarding inconsistent and unreliable results from reproxalap clinical trials during the period of November 3, 2023, to March 16, 2026. Shareholders who purchased ALDX shares within this class period are encouraged to contact the firm to learn about participating in a potential recovery.
ALDX DEADLINE: The Gross Law Firm Reminds Aldeyra Therapeutics, Inc. Investors of Upcoming Securities Class Action Deadline
The Gross Law Firm has issued a notice to shareholders of Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) regarding an upcoming securities class action deadline. The lawsuit alleges that Aldeyra Therapeutics issued false and misleading statements about the inconsistent results of its reproxalap clinical trials. Investors who purchased ALDX shares between November 3, 2023, and March 16, 2026, are encouraged to register for the class action, with a lead plaintiff deadline of May 29, 2026.
ALDX SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Aldeyra Therapeutics, Inc. Shareholders Have Opportunity to Lead Class Action Lawsuit!
Bronstein, Gewirtz and Grossman, LLC has announced a class action lawsuit against Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) and its officers. The lawsuit alleges that Aldeyra made false and misleading statements about the inconsistent results of its reproxalap drug clinical trials during the Class Period from November 3, 2023, to March 16, 2026. Investors who purchased Aldeyra securities during this period have until May 29, 2026, to request to be appointed as lead plaintiff.
ROSEN, A LEADING LAW FIRM, Encourages Aldeyra Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm - ALDX
Rosen Law Firm is encouraging investors of Aldeyra Therapeutics, Inc. to secure legal counsel before the May 29, 2026, lead plaintiff deadline in a securities class action lawsuit. The lawsuit alleges that Aldeyra made false or misleading statements regarding the inconsistent and unreliable results of its reproxalap drug candidate clinical trials. Investors who purchased Aldeyra securities between November 3, 2023, and March 16, 2026, may be entitled to compensation.
FinancialContent - ROSEN, TOP RANKED GLOBAL COUNSEL, Encourages Aldeyra Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm - ALDX
The Rosen Law Firm is reminding investors of Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) who purchased securities between November 3, 2023, and March 16, 2026, about an important May 29, 2026 lead plaintiff deadline in a securities class action. The lawsuit alleges that Aldeyra made false or misleading statements regarding the inconsistent results of its reproxalap clinical trials, leading to investor damages. Investors are encouraged to secure counsel to potentially recover losses through a contingency fee arrangement.
ALDX Investor Alert: Aldeyra Therapeutics Securities Fraud
Levi & Korsinsky, LLP has issued an investor alert regarding a securities fraud lawsuit against Aldeyra Therapeutics, Inc. (ALDX). The lawsuit alleges that Aldeyra made misleading statements about the efficacy of its lead dry eye disease candidate, reproxalap, leading to a significant stock value collapse after the FDA issued a Complete Response Letter. Investors who purchased ALDX securities between November 3, 2023, and March 16, 2026, and suffered losses, have until May 29, 2026, to file a motion seeking to be appointed as lead plaintiff.
ALDX Investor Alert: Aldeyra Therapeutics Securities Fraud
Levi & Korsinsky, LLP has issued an investor alert regarding a securities fraud lawsuit against Aldeyra Therapeutics (NASDAQ: ALDX). Investors who purchased ALDX securities between November 3, 2023, and March 16, 2026, and suffered losses, may seek to become lead plaintiff by the May 29, 2026 deadline. The lawsuit alleges that Aldeyra made misleading statements about the efficacy of its dry eye disease candidate, reproxalap, prior to an FDA Complete Response Letter that exposed issues with clinical trial evidence, leading to a significant stock price drop.
ALDX Investors Have Opportunity to Lead Aldeyra Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm
The Schall Law Firm has announced a class action lawsuit against Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) for alleged securities fraud, stemming from purportedly false and misleading statements about its reproxalap drug candidate's clinical trial results. Investors who purchased ALDX securities between November 3, 2023, and March 16, 2026, are encouraged to contact the firm to potentially lead the lawsuit before May 29, 2026. The firm claims that inconsistencies in trial results made the company's positive statements about the drug unreliable.
ALDX News | ALDEYRA THERAPEUTICS INC (NASDAQ:ALDX)
This article provides news and analysis for Aldeyra Therapeutics Inc. (NASDAQ: ALDX), primarily featuring announcements from various law firms regarding securities class action lawsuits against the company. Several law firms, including Schall Law, Faruqi & Faruqi, LLP, Pomerantz LLP, and The Rosen Law Firm, P. A., are encouraging investors to join class actions related to potential securities fraud. The updates span from 44 minutes to 9 days ago, all referencing upcoming deadlines for investors to secure counsel.
ALDX INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Aldeyra Therapeutics, Inc. Shareholders Have Opportunity to Lead Class Action Lawsuit!
Bronstein, Gewirtz and Grossman, LLC has announced a class action lawsuit against Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) and its officers. The lawsuit alleges that the company made misleading statements regarding the inconsistent results of its reproxalap clinical trials. Shareholders who purchased Aldeyra securities between November 3, 2023, and March 16, 2026, are encouraged to join the lawsuit, with a deadline of May 29, 2026, to request lead plaintiff status.
Bronstein, Gewirtz & Grossman LLC Urges Aldeyra Therapeutics, Inc. Investors to Act: Class Action Filed Alleging Investor Harm
Bronstein, Gewirtz & Grossman LLC has filed a class action lawsuit against Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) alleging investor harm due to misleading statements about the clinical trials of their drug candidate, reproxalap. The firm claims that the trial results were inconsistent and unreliable, rendering positive findings unmeaningful. Investors who purchased Aldeyra securities between November 3, 2023, and March 16, 2026, are encouraged to join the lawsuit, with a lead plaintiff deadline of May 29, 2026.
ALDX STOCKHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Aldeyra Therapeutics, Inc. Investors with Losses Have Opportunity to Lead Class Action Lawsuit!
Bronstein, Gewirtz and Grossman, LLC has announced a class action lawsuit against Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) and its officers. The lawsuit, filed on behalf of investors who purchased securities between November 3, 2023, and March 16, 2026, alleges that Aldeyra made false and misleading statements regarding the inconsistent results of its reproxalap clinical trials. Investors who suffered losses have until May 29, 2026, to apply to be lead plaintiff in the case.
Perceptive (ALDX) amendment shows 0% ownership; Joseph Edelman signs
An amendment to a Schedule 13G filing for Aldeyra Therapeutics (ALDX) discloses that Perceptive Advisors LLC, Joseph Edelman, and Perceptive Life Sciences Master Fund, Ltd. all report 0% beneficial ownership of the company's common stock. The filing confirms that each reporting person holds zero shares and less than 5% of the class, indicating an administrative update to their ownership status with no change to control or voting power. Joseph Edelman signed the amendment, which details zero sole or shared voting and dispositive power for the entities.
ALDX Investors Have Opportunity to Lead Aldeyra Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm
The Schall Law Firm is reminding investors of a class action lawsuit against Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) for alleged securities fraud. The lawsuit claims that Aldeyra made false and misleading statements regarding inconsistencies in clinical trials for its reproxalap drug candidate. Investors who purchased securities between November 3, 2023, and March 16, 2026, are encouraged to contact the firm by May 29, 2026, to discuss their rights.
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Aldeyra Therapeutics, Inc. Of Class Action Lawsuit and Upcoming Deadlines - ALDX
Pomerantz LLP has filed a class action lawsuit against Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) on behalf of investors who suffered losses. The lawsuit stems from Aldeyra's receipt of a Complete Response Letter from the FDA for its dry eye disease drug candidate, reproxalap, citing a lack of substantial efficacy evidence. Following this news, Aldeyra's stock price significantly dropped by 70.69% on March 17, 2026.
ALDX INVESTOR NOTICE: Faruqi & Faruqi, LLP Reminds Aldeyra Therapeutics (ALDX) Investors of Securities Class Action Deadline on May 29, 2026
Faruqi & Faruqi, LLP is investigating potential claims against Aldeyra Therapeutics, Inc. (ALDX) and reminds investors of the May 29, 2026, deadline to seek the role of lead plaintiff in a federal securities class action. The lawsuit alleges that Aldeyra made false and misleading statements regarding the inconsistent results of their reproxalap clinical trials and that the FDA rejected their NDA for reproxalap due to insufficient efficacy evidence, causing a significant stock price drop. Investors who purchased Aldeyra securities between November 3, 2023, and March 16, 2026, and suffered losses are encouraged to contact the firm.
Bronstein, Gewirtz & Grossman LLC Urges Aldeyra
Bronstein, Gewirtz & Grossman LLC has filed a class action lawsuit against Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) alleging investor harm due to false and misleading statements regarding the inconsistent results of reproxalap clinical trials. Investors who purchased Aldeyra securities between November 3, 2023, and March 16, 2026, are encouraged to join the lawsuit, with a lead plaintiff deadline of May 29, 2026. The firm operates on a contingency fee basis, seeking to recover damages for affected investors.
ALDX Investor Alert: Aldeyra Therapeutics Securities Fraud Lawsuit - Investors With Losses May Seek to Lead the Class Action After Executive Allegedly Approved Misleading Disclosures: Levi & Korsinsky
Levi & Korsinsky, LLP has issued an investor alert regarding a securities fraud lawsuit against Aldeyra Therapeutics, Inc. (ALDX). The lawsuit names Michael Alferi, Head of Finance, as an individual defendant, alleging he approved misleading disclosures related to the company's dry eye disease drug, reproxalap, which was rejected by the FDA. Investors who suffered losses between November 3, 2023, and March 16, 2026, are encouraged to contact the law firm to potentially lead the class action, with a lead plaintiff deadline of May 29, 2026.
ALDX INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Reminds Investors of Aldeyra Therapeutics, Inc. to Contact the Firm Today!
Bronstein, Gewirtz and Grossman, LLC has issued an investor alert, reminding investors of Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) to contact the firm regarding a class action lawsuit. The lawsuit alleges that Aldeyra made false and misleading statements concerning the inconsistent results of its reproxalap clinical trials. Investors who purchased Aldeyra securities between November 3, 2023, and March 16, 2026, are encouraged to join the case, with a lead plaintiff deadline of May 29, 2026.
ALDX DEADLINE NOTICE: Aldeyra Therapeutics, Inc. Investors Encouraged to Contact Kirby McInerney LLP By May 29, 2026
Kirby McInerney LLP is encouraging investors of Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) to contact them regarding a securities fraud class action lawsuit. Investors who suffered losses on their Aldeyra investments between November 3, 2023, and March 16, 2026, have until May 29, 2026, to apply to be a lead plaintiff. The lawsuit alleges Aldeyra failed to disclose inconsistencies in clinical trials for its drug candidate reproxalap, leading to a significant stock price drop after the FDA issued a Complete Response Letter.
ROSEN, THE FIRST FILING FIRM, Encourages Aldeyra Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm - ALDX
The Rosen Law Firm is encouraging investors of Aldeyra Therapeutics, Inc. to secure legal counsel before the May 29, 2026, lead plaintiff deadline in a securities class action lawsuit. The lawsuit alleges that Aldeyra made false and misleading statements regarding the inconsistent results of its reproxalap clinical trials. Investors who purchased ALDX securities during the Class Period (November 3, 2023, to March 16, 2026) may be entitled to compensation.
ALDX DEADLINE: The Gross Law Firm Reminds Aldeyra Therapeutics, Inc. Investors of Upcoming Securities Class Action Deadline
The Gross Law Firm is notifying investors of Aldeyra Therapeutics, Inc. (ALDX) about an upcoming deadline for a securities class action lawsuit. Investors who purchased shares between November 3, 2023, and March 16, 2026, are encouraged to contact the firm regarding being appointed lead plaintiff before the May 29, 2026, deadline. The lawsuit alleges that Aldeyra made false and misleading statements about the inconsistencies and unreliability of reproxalap clinical trial results, artificially inflating the company's stock.
Portnoy Law Firm Announces Class Action on Behalf of Aldeyra Therapeutics, Inc. Investors
The Portnoy Law Firm has announced a class action lawsuit against Aldeyra Therapeutics, Inc. on behalf of investors who purchased securities between November 3, 2023, and March 16, 2026. The lawsuit alleges that Aldeyra failed to disclose inconsistencies in its reproxalap clinical trials and that statements about its business, operations, and prospects were false and misleading. This follows a Complete Response Letter from the SEC on March 17, 2026, which questioned the efficacy and reliability of the drug's trial results, leading to a significant drop in Aldeyra's stock price.
ALDX DEADLINE: The Gross Law Firm Reminds Aldeyra Therapeutics, Inc. Investors of Upcoming Securities Class Action Deadline
The Gross Law Firm is reminding investors of Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) about an upcoming securities class action deadline. Shareholders who purchased ALDX shares between November 3, 2023, and March 16, 2026, are encouraged to contact the firm, as the complaint alleges the company made materially false or misleading statements regarding inconsistent and unreliable clinical trial results. The deadline to seek lead plaintiff appointment in this class action is May 29, 2026.
ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Aldeyra Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm - ALDX
The Rosen Law Firm is encouraging investors of Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) to join a securities class action lawsuit before the May 29, 2026 lead plaintiff deadline. The lawsuit alleges that Aldeyra made false and misleading statements regarding the inconsistent results of its reproxalap clinical trials. Investors who purchased Aldeyra securities between November 3, 2023, and March 16, 2026, may be entitled to compensation.
Bragar Eagel & Squire, P.C. Encourages Aldeyra Therapeutics, Inc. Investors with Large Losses to Contact the Firm Regarding Their Rights Before May 29th
Bragar Eagel & Squire, P.C. has filed a class action lawsuit against Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) on behalf of investors who purchased or acquired securities between November 3, 2023, and March 16, 2026. The lawsuit alleges that Aldeyra made false and misleading statements regarding the inconsistent results of its reproxalap clinical trials. Investors with losses are encouraged to contact the firm before May 29, 2026, to apply for lead plaintiff status.
ALDX Investor Alert: Aldeyra Therapeutics Securities Fraud
Levi & Korsinsky, LLP announced a securities class action lawsuit against Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) for alleged securities fraud. The lawsuit involves investors who held ALDX shares between November 3, 2023, and March 16, 2026, after the FDA rejected Aldeyra's lead drug candidate reproxalap due to inconsistent trial data, causing a significant stock drop. The firm is encouraging institutional investors to evaluate lead plaintiff opportunities, with the deadline to apply set for May 29, 2026.
ALDX Investors Have Opportunity to Lead Aldeyra Therapeutics, Inc. Securities Fraud Lawsuit Filed by The Rosen Law Firm
The Rosen Law Firm reminds investors who purchased Aldeyra Therapeutics, Inc. (ALDX) securities between November 3, 2023, and March 16, 2026, of the May 29, 2026, lead plaintiff deadline for a securities fraud class action lawsuit. The lawsuit alleges that Aldeyra made false and misleading statements regarding the inconsistent and unreliable results of its reproxalap drug candidate clinical trials. Investors can join the class action to seek compensation.
ALDX SEC Filings - Aldeyra Therapeutics Inc 10-K, 10-Q, 8-K Forms
This page provides access to Aldeyra Therapeutics Inc. (ALDX) SEC filings, including 10-K, 10-Q, and 8-K reports, along with insider trading forms. It highlights recent material events such as the PDUFA target date extension for reproxalap, an SPA agreement for ADX-2191, and financial updates from their Q2-25 10-Q. The platform uses AI to summarize filings and track company developments.
Bronstein, Gewirtz & Grossman LLC Urges Aldeyra Therapeutics, Inc. Investors to Act: Class Action Filed Alleging Investor Harm
Bronstein, Gewirtz & Grossman, LLC has filed a class action lawsuit against Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) alleging investor harm due to false and misleading statements and/or failure to disclose that their drug candidate, reproxalap, had inconsistent clinical trial results. The firm encourages investors who purchased Aldeyra securities between November 3, 2023, and March 16, 2026, to join the lawsuit by May 26, 2026. The lawsuit operates on a contingency fee basis, meaning investors will not incur out-of-pocket expenses unless the firm is successful.
Bronstein, Gewirtz & Grossman LLC Urges Aldeyra Therapeutics, Inc. Investors to Act: Class Action Filed Alleging Investor Harm
Bronstein, Gewirtz & Grossman, LLC has filed a class action lawsuit against Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) for alleged violations of federal securities laws. The lawsuit claims that Aldeyra made false and misleading statements regarding the inconsistent results of its reproxalap clinical trials. Investors who purchased Aldeyra securities between November 3, 2023, and March 16, 2026, are encouraged to join the case, with a lead plaintiff deadline of May 29, 2026.
ROSEN, LEADING INVESTOR COUNSEL, Encourages Aldeyra Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by The Firm - ALDX
Rosen Law Firm is reminding investors of Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) who purchased securities between November 3, 2023, and March 16, 2026, about the May 29, 2026 lead plaintiff deadline in a securities class action. The lawsuit alleges that Aldeyra made false and misleading statements regarding inconsistent clinical trial results for its drug candidate, reproxalap. Investors are encouraged to contact the firm to potentially join the class action and seek compensation.
Aldeyra Therapeutics Inc expected to post a loss of 13 cents a share - Earnings Preview
Aldeyra Therapeutics Inc (ALDX) is projected to report a loss of 13 cents per share. This information comes from a Refinitiv earnings preview.
ALDX Investor Alert: Aldeyra Therapeutics Securities Fraud Lawsuit - Investors With Losses May Seek to Lead the Class Action After Company Allegedly Misrepresented Clinical Trial Results: SueWallSt
SueWallSt has issued an investor alert regarding a securities fraud class action lawsuit filed against Aldeyra Therapeutics, Inc. (NASDAQ: ALDX). The lawsuit alleges that the company made materially false and misleading statements about the efficacy and consistency of its lead drug candidate, reproxalap, in clinical trials between November 3, 2023, and March 16, 2026. This led to a 70.7% stock drop after the FDA rejected reproxalap due to inconsistent study results. Investors who purchased shares during this period and suffered losses may be eligible to join the lawsuit, with a lead plaintiff deadline of May 29, 2026.
ROSEN, SKILLED INVESTOR COUNSEL, Encourages Aldeyra Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm - ALDX
Rosen Law Firm is reminding investors of Aldeyra Therapeutics, Inc. who purchased securities between November 3, 2023, and March 16, 2026, about the May 29, 2026 lead plaintiff deadline in a securities class action. The lawsuit alleges that Aldeyra made false or misleading statements regarding the inconsistent results of its reproxalap drug candidate clinical trials, which rendered purported positive findings unreliable. The firm encourages affected investors to secure counsel and join the class action to potentially recover damages.
ALDX DEADLINE: The Gross Law Firm Reminds Aldeyra
The Gross Law Firm is alerting investors of Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) about an upcoming deadline for a securities class action lawsuit. Shareholders who purchased ALDX shares between November 3, 2023, and March 16, 2026, are encouraged to contact the firm regarding their potential involvement as lead plaintiff. The lawsuit alleges that Aldeyra made false and misleading statements concerning the inconsistency and unreliability of reproxalap clinical trial results.
Number of shareholders of Aldeyra Therapeutics, Inc. – NASDAQ:ALDX
This article displays information regarding the number of shareholders for Aldeyra Therapeutics, Inc. (NASDAQ: ALDX). It provides a general overview with no specific shareholder data presented in the provided text. The content primarily consists of article navigation and footer information rather than detailed financial figures.
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Aldeyra Therapeutics, Inc. Of Class Action Lawsuit and Upcoming Deadlines - ALDX
Pomerantz LLP has filed a class action lawsuit against Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) on behalf of investors who suffered losses. The lawsuit stems from Aldeyra's announcement on March 17, 2026, regarding a Complete Response Letter from the FDA for its dry eye disease drug, reproxalap, citing a lack of demonstrated efficacy, which caused a significant drop in its stock price. Investors who purchased Aldeyra securities during the Class Period have until May 29, 2026, to seek appointment as Lead Plaintiff.
[10-Q] Aldeyra Therapeutics, Inc. Quarterly Earnings Report
Aldeyra Therapeutics, Inc. (ALDX) has filed its quarterly earnings report (10-Q) for the period ended March 31, 2026, revealing a net loss of $3.5 million, a significant improvement from $9.9 million in the same period last year due to decreased research and development and general and administrative expenses. The company's cash and cash equivalents stood at $65.0 million, and it anticipates these funds will be sufficient to cover operating expenses and debt obligations into the second half of 2028. Aldeyra is highly reliant on the successful commercialization of reproxalap, currently awaiting potential FDA approval, and acknowledged risks associated with regulatory hurdles, intense competition, and the necessity of securing additional funding for future development and commercialization efforts.
ALDX INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Aldeyra Therapeutics, Inc. Shareholders with Losses Have Opportunity to Lead Class Action Lawsuit!
Bronstein, Gewirtz and Grossman, LLC has announced a class action lawsuit against Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) and its officers. The lawsuit seeks to recover damages for investors who purchased Aldeyra securities between November 3, 2023, and March 16, 2026, alleging that the company made false and misleading statements regarding the inconsistent results of its reproxalap clinical trials. Shareholders with losses are encouraged to join the lawsuit, with May 29, 2026, as the deadline to request to be appointed lead plaintiff.
